ATE383375T1 - Wti-modifiziertes peptid - Google Patents

Wti-modifiziertes peptid

Info

Publication number: ATE383375T1
Authority: AT; Austria
Prior art keywords: wti; modified peptide; active ingredient; peptide; dna
Prior art date: 2001-03-22

Application number

AT02708646T

Other languages

English (en)

Inventor

Haruo Sugiyama

Original Assignee

Int Inst Cancer Immunology Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-22

Filing date

2002-03-22

Publication date

2008-01-15

2002-03-22 Application filed by Int Inst Cancer Immunology Inc filed Critical Int Inst Cancer Immunology Inc

2008-01-15 Application granted granted Critical

2008-01-15 Publication of ATE383375T1 publication Critical patent/ATE383375T1/de

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
239000004480 active ingredient Substances 0.000 abstract 2
VXDXZGYXHIADHF-YJRXYDGGSA-N Cys-Tyr-Thr Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VXDXZGYXHIADHF-YJRXYDGGSA-N 0.000 abstract 1
108010041986 DNA Vaccines Proteins 0.000 abstract 1
229940021995 DNA vaccine Drugs 0.000 abstract 1
YNOVBMBQSQTLFM-DCAQKATOSA-N Met-Asn-Leu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O YNOVBMBQSQTLFM-DCAQKATOSA-N 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
NAQBQJOGGYGCOT-QEJZJMRPSA-N Trp-Asn-Gln Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O NAQBQJOGGYGCOT-QEJZJMRPSA-N 0.000 abstract 1
150000001413 amino acids Chemical group 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
229940022399 cancer vaccine Drugs 0.000 abstract 1
238000009566 cancer vaccine Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Zoology (AREA)
Toxicology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Hematology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Saccharide Compounds (AREA)

AT02708646T 2001-03-22 2002-03-22 Wti-modifiziertes peptid ATE383375T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2001083250		2001-03-22

Publications (1)

Publication Number	Publication Date
ATE383375T1 true ATE383375T1 (de)	2008-01-15

Family

ID=18939092

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02708646T ATE383375T1 (de)	2001-03-22	2002-03-22	Wti-modifiziertes peptid

Country Status (13)

Country	Link
US (2)	US20040097703A1 (de)
EP (1)	EP1371664B1 (de)
JP (2)	JP3728439B2 (de)
KR (1)	KR100863853B1 (de)
CN (1)	CN1281625C (de)
AT (1)	ATE383375T1 (de)
BR (1)	BRPI0208183B8 (de)
CA (1)	CA2440303C (de)
DE (1)	DE60224508T2 (de)
ES (1)	ES2298353T3 (de)
HK (1)	HK1070078A1 (de)
TW (1)	TWI318630B (de)
WO (1)	WO2002079253A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU4932199A (en)	1998-07-31	2000-02-21	Haruo Sugiyama	Cancer antigens based on tumor suppressor gene wt1 product
CA2440303C (en) *	2001-03-22	2013-03-19	Haruo Sugiyama	Wt1 modified peptide
WO2003028757A1 (fr) *	2001-09-28	2003-04-10	Haruo Sugiyama	Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes
EP1447092A4 (de) *	2001-09-28	2007-07-11	Haruo Sugiyama	Neues verfahren zur induktion von antigenspezifischen t-zellen
JP2003243616A (ja)	2002-02-20	2003-08-29	Seiko Epson Corp	半導体装置の製造方法
CN101113163B (zh) *	2002-06-12	2010-10-06	株式会社国际癌症免疫研究所	Hla-a24限制性癌抗原肽
EP1550453B1 (de) *	2002-09-12	2015-05-27	International Institute of Cancer Immunology, Inc.	Präparat eines peptids eines krebs-antigens
DE60329201D1 (de) *	2002-09-20	2009-10-22	Chugai Pharmaceutical Co Ltd	Substituierte wt1-peptide
ATE444969T1 (de) *	2003-01-15	2009-10-15	Int Inst Cancer Immunology Inc	Dimerisiertes peptid
EP2338509B1 (de)	2003-06-27	2014-06-18	International Institute of Cancer Immunology, Inc.	Verfahren zur Auswahl von für den WT1-Impfstoff geeigneten Patienten
KR20130062368A (ko)	2003-11-05	2013-06-12	인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드	Ｗｔ１ 유래의 ｈｌａ-ｄｒ 결합성 항원 펩티드
PL1731605T3 (pl) *	2004-03-31	2010-08-31	Int Inst Cancer Immunology Inc	Nowotworowe peptydy antygenowe pochodzące z WT1
CA2626238C (en)	2005-10-17	2015-10-06	Sloan Kettering Institute For Cancer Research	Wt1 hla class ii-binding peptides and compositions and methods comprising same
CA2631292C (en) *	2005-11-30	2014-05-06	International Institute Of Cancer Immunology, Inc.	Derivatised wt1 cancer antigen peptides and their use
SI1988163T1 (sl) *	2006-02-22	2012-09-28	Int Inst Cancer Immunology Inc	HLA-A*3303-omejen WT1 peptid in farmacevtski sestavek, ki ga vsebuje
EP3834836A1 (de)	2006-04-10	2021-06-16	Memorial Sloan Kettering Cancer Center	Immunogene wt-1-peptide und verwendungen davon
NZ592510A (en) *	2006-12-28	2012-11-30	Int Inst Cancer Immunology Inc	HLA-A*1101-restricted WTI peptide and pharmaceutical composition comprising the same
NZ599161A (en) *	2007-02-27	2012-07-27	Int Inst Cancer Immunology Inc	Method for activation of helper t cell and composition for use in the method
EP3173480A3 (de)	2007-03-05	2017-08-16	International Institute of Cancer Immunology, Inc.	Krebs-antigen-spezifisches t-zell-rezeptorgen, durch das gen codiertes peptid und verwendung davon
US8557779B2 (en)	2007-12-05	2013-10-15	International Institute Of Cancer Immunology, Inc.	Cancer vaccine composition
TW201623616A (zh)	2010-10-05	2016-07-01	癌免疫研究所股份有限公司	用於活化細胞毒性ｔ細胞的方法及組成物，及用於細胞毒性ｔ細胞之活化誘導物
US9803246B2 (en)	2011-06-28	2017-10-31	International Institute Of Cancer Immunology, Inc.	Receptor gene for peptide cancer antigen-specific T cell
US9539299B2 (en) *	2011-10-27	2017-01-10	International Institute Of Cancer Immunology, Inc.	Combination therapy with WT1 peptide vaccine and temozolomide
EP2802347B1 (de)	2012-01-13	2019-01-09	Memorial Sloan Kettering Cancer Center	Immunogene wt-1-peptide und verfahren zur verwendung davon
ES2655031T3 (es)	2012-07-02	2018-02-16	Sumitomo Dainippon Pharma Co., Ltd.	Preparación transdérmica de péptido antigénico del cáncer
CN104797711B (zh) *	2012-09-12	2018-09-21	株式会社癌免疫研究所	抗原特异性辅助性t细胞受体基因
NZ708990A (en)	2012-12-17	2020-03-27	Int Inst Cancer Immunology Inc	Method for activating helper t cell
CN116789792A (zh) *	2013-01-15	2023-09-22	纪念斯隆凯特林癌症中心	免疫原性wt-1肽和其使用方法
US10815273B2 (en)	2013-01-15	2020-10-27	Memorial Sloan Kettering Cancer Center	Immunogenic WT-1 peptides and methods of use thereof
JP6250288B2 (ja) *	2013-01-30	2017-12-20	株式会社医学生物学研究所	Ｔ細胞レセプターおよびその利用
RU2697443C2 (ru)	2013-02-05	2019-08-14	Нитто Денко Корпорейшн	Препарат противораковой вакцины, содержащий пептид wt1, в форме ленты трансдермального введения
CN103961702B (zh)	2013-02-05	2019-04-09	日东电工株式会社	粘膜给予用wt1肽癌症疫苗组合物
JP6512568B2 (ja)	2013-02-05	2019-05-15	日東電工株式会社	経皮投与用ｗｔ１ペプチド癌ワクチン組成物
RU2685933C2 (ru)	2013-02-05	2019-04-23	Нитто Денко Корпорейшн	Композиция противораковой вакцины, содержащая пептид wt1, для трансдермального введения
JP6294868B2 (ja)	2013-03-12	2018-03-14	大日本住友製薬株式会社	液体水性組成物
US10588952B2 (en)	2013-03-29	2020-03-17	Sumitomo Dainippon Pharma Co., Ltd.	Conjugate vaccine using trimming function of ERAP1
AU2014244860B2 (en) *	2013-03-29	2018-07-26	International Institute Of Cancer Immunology, Inc.	WT1-antigen peptide conjugate vaccine
ES2954899T3 (es)	2013-05-13	2023-11-27	Int Inst Cancer Immunology Inc	Procedimiento para predecir el efecto clínico de una inmunoterapia
CN106029699B (zh)	2014-02-26	2019-07-19	泰来有限公司	Wt1抗原性多肽和含有该多肽的抗肿瘤剂
US10471136B2 (en)	2014-09-27	2019-11-12	Sumitomo Dainippon Pharma Co., Ltd.	Pharmaceutical composition for injection
US20200016255A1 (en)	2016-11-30	2020-01-16	Sumitomo Dainippon Pharma Co., Ltd.	Wt1 helper peptides and combinations of wt1 helper peptide and conjugate of cancer antigen peptides
EP3604325A4 (de)	2017-03-30	2021-01-13	Sumitomo Dainippon Pharma Co., Ltd.	Wt1-krebs-antigen-peptid und peptid-konjugat-körper damit
US20210338587A1 (en)	2018-09-28	2021-11-04	Sumitomo Dainippon Pharma Co., Ltd.	Injectable composition
TW202027777A (zh)	2018-10-05	2020-08-01	日商癌免疫研究所股份有限公司	良性腫瘤之預防或治療藥
TW202045528A (zh)	2019-02-28	2020-12-16	日商大日本住友製藥股份有限公司	選擇可期待用於治療或預防癌之醫藥組合物之效果之對象之方法
CA3182959A1 (en)	2020-05-12	2021-11-18	Sumitomo Pharma Co., Ltd.	Pharmaceutical composition for treating cancer
CN111647066B (zh) *	2020-07-01	2020-12-18	维肽瀛(上海)生物技术有限公司	Wt1多肽肿瘤抑制剂
EP4385519A1 (de)	2021-08-12	2024-06-19	International Institute of Cancer Immunology, Inc.	Pharmazeutische zusammensetzung und verfahren zur behandlung oder prävention von krebs

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6122018A (ja)	1984-07-06	1986-01-30	Green Cross Corp:The	癌免疫療法増強剤
WO1991007509A1 (en)	1989-11-13	1991-05-30	Massachusetts Institute Of Technology	Localization and characterization of the wilms's tumor gene
JPH09506866A (ja)	1993-12-14	1997-07-08	ジョーンズホプキンスユニバーシティースクールオブメディシン	医薬として活性のある物質の免疫療法のための放出制御
US5622835A (en)	1994-04-28	1997-04-22	The Wistar Institute Of Anatomy & Biology	WT1 monoclonal antibodies
DK0772619T4 (da)	1994-07-15	2011-02-21	Univ Iowa Res Found	Immunmodulatoriske oligonukleotider
JP3904260B2 (ja)	1995-06-01	2007-04-11	岸本忠三	ウイルムス腫瘍遺伝子（ｗｔ１）に対するアンチセンスオリゴヌクレオチド誘導体を含んで成る白血病細胞増殖阻害剤
DE69636339T2 (de) *	1995-06-01	2007-07-19	Kishimoto, Tadamitsu, Tondabayashi	Wachstumsinhibitor gegen leukämische zellen, der antisense-oligonukleotidderivate gegen das wilms-tumorgen enthält
EP1702518A1 (de) *	1995-09-19	2006-09-20	Bayer BioScience GmbH	Pflanzen, die eine modifizierte Stärke synthetisieren, Verfahren zu ihrer Herstellung sowie modifizierte Stärke
US20030092656A1 (en) *	1997-07-16	2003-05-15	Haruo Sugiyama	Therapeutic agents for treatment of solid tumors comprising an expression-inhibiting sustance against Wilms' tumor gene (WT1)
JP4789095B2 (ja)	1997-07-16	2011-10-05	治夫杉山	ウイルムス腫瘍遺伝子（ｗｔ１）に対する発現阻害物質を含んで成る固形腫瘍治療剤
US5985264A (en)	1998-03-05	1999-11-16	The Medical College Of Ohio	IL-12 Stimulation of Neonatal immunity
AU4932199A (en)	1998-07-31	2000-02-21	Haruo Sugiyama	Cancer antigens based on tumor suppressor gene wt1 product
US7901693B2 (en) *	1998-09-30	2011-03-08	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
US20030215458A1 (en) *	1998-09-30	2003-11-20	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) *	1998-09-30	2010-02-02	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
CZ20011144A3 (cs) *	1998-09-30	2002-06-12	Corixa Corporation	Prostředky a způsoby pro WT1 specifickou imunoterapii
US20030072767A1 (en) *	1998-09-30	2003-04-17	Alexander Gaiger	Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) *	1998-09-30	2003-12-25	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
US20030039635A1 (en) *	1998-09-30	2003-02-27	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) *	2000-10-09	2006-12-05	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) *	1998-11-02	1998-12-30	Imp College Innovations Ltd	Immunotherapeutic methods and molecules
EP1140163A2 (de)	1999-01-12	2001-10-10	SMITHKLINE BEECHAM BIOLOGICALS s.a.	Zusammensetzung enthaltend hepatitis b impfstof und antivirale
PT1031346E (pt)	1999-01-27	2002-09-30	Idea Ag	Vacinacao nao invasiva atraves da pele
ATE320266T1 (de)	1999-07-22	2006-04-15	Dainippon Sumitomo Pharma Co	Induktion von antigen-spezifischen t-zellen durch interferon
JP2001089389A (ja)	1999-07-22	2001-04-03	Sumitomo Pharmaceut Co Ltd	抗原特異的ｔ細胞の誘導剤
EP1261711A2 (de)	2000-02-22	2002-12-04	Corixa Corporation	Zusammensetzungen und methoden zur diagnose und therapie von malignen mesotheliom
CA2440303C (en)	2001-03-22	2013-03-19	Haruo Sugiyama	Wt1 modified peptide
US7553494B2 (en) *	2001-08-24	2009-06-30	Corixa Corporation	WT1 fusion proteins
WO2003028757A1 (fr) *	2001-09-28	2003-04-10	Haruo Sugiyama	Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes
EP1447092A4 (de) *	2001-09-28	2007-07-11	Haruo Sugiyama	Neues verfahren zur induktion von antigenspezifischen t-zellen
CN101113163B (zh)	2002-06-12	2010-10-06	株式会社国际癌症免疫研究所	Hla-a24限制性癌抗原肽
EP1550453B1 (de)	2002-09-12	2015-05-27	International Institute of Cancer Immunology, Inc.	Präparat eines peptids eines krebs-antigens
DE60329201D1 (de)	2002-09-20	2009-10-22	Chugai Pharmaceutical Co Ltd	Substituierte wt1-peptide
ATE444969T1 (de)	2003-01-15	2009-10-15	Int Inst Cancer Immunology Inc	Dimerisiertes peptid
EP2338509B1 (de)	2003-06-27	2014-06-18	International Institute of Cancer Immunology, Inc.	Verfahren zur Auswahl von für den WT1-Impfstoff geeigneten Patienten
KR20130062368A (ko)	2003-11-05	2013-06-12	인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드	Ｗｔ１ 유래의 ｈｌａ-ｄｒ 결합성 항원 펩티드
PL1731605T3 (pl)	2004-03-31	2010-08-31	Int Inst Cancer Immunology Inc	Nowotworowe peptydy antygenowe pochodzące z WT1

2002
- 2002-03-22 CA CA2440303A patent/CA2440303C/en not_active Expired - Lifetime
- 2002-03-22 WO PCT/JP2002/002794 patent/WO2002079253A1/ja active IP Right Grant
- 2002-03-22 CN CNB028070259A patent/CN1281625C/zh not_active Expired - Lifetime
- 2002-03-22 AT AT02708646T patent/ATE383375T1/de not_active IP Right Cessation
- 2002-03-22 US US10/471,835 patent/US20040097703A1/en not_active Abandoned
- 2002-03-22 JP JP2002577877A patent/JP3728439B2/ja not_active Expired - Lifetime
- 2002-03-22 TW TW091105633A patent/TWI318630B/zh not_active IP Right Cessation
- 2002-03-22 BR BRPI0208183 patent/BRPI0208183B8/pt not_active IP Right Cessation
- 2002-03-22 KR KR1020037011790A patent/KR100863853B1/ko active IP Right Grant
- 2002-03-22 ES ES02708646T patent/ES2298353T3/es not_active Expired - Lifetime
- 2002-03-22 EP EP02708646A patent/EP1371664B1/de not_active Expired - Lifetime
- 2002-03-22 DE DE60224508T patent/DE60224508T2/de not_active Expired - Lifetime
2005
- 2005-03-18 HK HK05102382A patent/HK1070078A1/xx not_active IP Right Cessation
- 2005-08-08 JP JP2005229180A patent/JP3819930B2/ja not_active Expired - Lifetime
2009
- 2009-09-02 US US12/552,660 patent/US8105604B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN1531553A (zh)	2004-09-22
EP1371664A1 (de)	2003-12-17
JP3728439B2 (ja)	2005-12-21
KR20030084970A (ko)	2003-11-01
EP1371664A4 (de)	2006-03-22
US20090325886A1 (en)	2009-12-31
US8105604B2 (en)	2012-01-31
JP2006034296A (ja)	2006-02-09
TWI318630B (en)	2009-12-21
CA2440303C (en)	2013-03-19
BR0208183A (pt)	2004-03-02
EP1371664B1 (de)	2008-01-09
JPWO2002079253A1 (ja)	2004-07-22
BRPI0208183B8 (pt)	2021-05-25
KR100863853B1 (ko)	2008-10-15
CN1281625C (zh)	2006-10-25
HK1070078A1 (en)	2005-06-10
US20040097703A1 (en)	2004-05-20
ES2298353T3 (es)	2008-05-16
DE60224508T2 (de)	2008-12-24
WO2002079253A1 (fr)	2002-10-10
CA2440303A1 (en)	2002-10-10
JP3819930B2 (ja)	2006-09-13
BRPI0208183B1 (pt)	2018-08-28
DE60224508D1 (de)	2008-02-21

Legal Events

Date	Code	Title	Description
2008-07-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60224508D1 (de)	2008-02-21	Wti-modifiziertes peptid
MXPA04000597A (es)	2004-04-20	Peptidos novedosos de la proteina g del virus sincicial respiratorio (rsv), y su uso en una vacuna.
WO2002059143A3 (en)	2004-01-22	Therapeutic peptides for demyelinating conditions
NO20073914L (no)	2004-03-10	Biologisk aktive peptider
IS2670B (is)	2010-09-15	Bóluefni og notkun þar á til meðhöndlunar á blandaðri hreyfitaugahrörnun
MXPA03010684A (es)	2005-11-04	Peptidos y el uso de los mismos para oscurecer la piel.
BR0214363A (pt)	2004-10-26	Anticorpo, uso de um anticorpo, medicamento, método de fabricação de um medicamento e pacote farmacêutico para o tratamento de infecção
NO20025064L (no)	2002-12-20	RGO koblet til peptider
ATE469655T1 (de)	2010-06-15	Bakteriophagenvermittelte impfung
CY1109946T1 (el)	2014-09-10	Τροποποιημενα πεπτιδια και η χρηση τους για τη θεραπεια αυτοανοσων νοσων
ATE323722T1 (de)	2006-05-15	Antimikrobiell wirkendes peptid
WO2002058725A3 (fr)	2003-01-09	Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
DK1268522T3 (da)	2009-01-12	LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler
NZ513549A (en)	2003-03-28	Malaria vaccine
EP1557466A4 (de)	2006-02-08	Tumorantigenprotein und dessen verwendung
ES2176363T3 (es)	2002-12-01	Peptidos de la proteina gag del vih, su preparacion y su uso.
WO2001090139A3 (en)	2002-06-20	A ligand for enhancing oral and cns delivery of biological agents
HUP0402160A2 (hu)	2005-01-28	T-sejt-epitópok a karboxipeptidáz-G2-ben
FR2819256B1 (fr)	2004-04-30	Polypeptide induisant des anticorps neutralisant le vih
IT1307333B1 (it)	2001-10-30	Peptidi derivati dall'allergene parj2 del polline di parietariajudaica.
BR0107799A (pt)	2002-10-22	Proteìna de interação de wt1 wtip
WO2003030843A3 (de)	2003-08-21	Haarbehandlungsmittel